复合确认残疾恶化/进展是多发性硬化临床试验的有用终点
该研究基于6项罗氏Ⅲ期试验的4979例MS患者个体数据及9项已发表研究的人群数据,分析T25FWT或9HPT事件与后续EDSS事件的关系。结果显示T25FWT或9HPT恶化可预测EDSS恶化,且T25FWT的治疗效应与EDSS的治疗效应相关(Spearman相关系数0.82)。
要点
- T25FWT事件与后续EDSS事件风险增加相关(HR 2.11-5.20)。
- 9HPT事件与后续EDSS事件风险增加相关(HR 1.47-2.66)。
- T25FWT治疗效应可预测EDSS治疗效应(相关系数0.82)。
核心结论
- T25FWT或9HPT恶化是EDSS恶化的前兆,T25FWT的治疗效应与EDSS的治疗效应相关,支持cCDW/cCDP作为MS试验中进展的主要结局。
研究设计与样本
- 分析(i):6项罗氏申办的Ⅲ期试验,共4979例MS患者(RRMS 1225例、RMS 1656例、PMS 922例、PPMS 1171例),数据截止2022年11月。
- 分析(ii):9项已发表研究,报告EDSS及cCDP或T25FWT或9HPT事件的治疗效应。
主要发现
- 所有试验中,T25FWT事件与后续EDSS事件风险增加相关(HR 2.11-5.20,p值0.07-<0.001)。
- 9HPT事件与后续EDSS事件风险增加相关(HR 1.47-2.66,p值0.24-<0.001)。
- 前96周无EDSS事件的患者中,前96周T25FWT事件与后续EDSS事件风险增加相关(HR 1.74-3.26,p值0.01-<0.001),9HPT事件亦相关(HR 1.45-3.08,p值0.45-<0.001)。
- 有T25FWT或9HPT事件的患者更可能在最终访视时MSIS-29身体子量表较基线变化≥8分(风险比:T25FWT 1.45-2.17,p值0.004-<0.001;9HPT 1.26-1.87,p值0.15-0.03)。
- 9项研究中,T25FWT事件的治疗效应可预测EDSS事件的治疗效应(Spearman相关系数0.82,95%CI 0.34-0.96,p=0.005)。
临床怎么用
- 性能测试恶化可预测EDSS恶化,支持将cCDW/cCDP作为MS试验中进展的主要结局。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sensitive and meaningful disability worsening measures remain an unmet medical need in multiple sclerosis (MS). Composite confirmed disability worsening/progression (cCDW/cCDP) combines the Expanded Disability Status Scale (EDSS) with performance tests of ambulation and dexterity (Timed 25-Foot Walk Test [T25FWT] and Nine-Hole Peg Test [9HPT]). We assessed the relation of changes in these measures to understand the utility of cCDW/cCDP as an endpoint for MS trials. METHODS: Clinical trials measuring all components of cCDW were selected for the analysis of (i) individual patient-level data from Roche-sponsored MS studies to characterize the association between performance-test changes and subsequent EDSS changes and (ii) population-level data from published studies reporting treatment effects on EDSS and either cCDP or T25FWT or 9HPT events to examine the relationship between treatment effects on T25FWT and EDSS events. RESULTS: Analysis (i): 6 Roche-sponsored Phase III trials comprising 4,979 patients with relapsing-remitting MS (RRMS; n = 1,225), relapsing MS (RMS; n = 1,656), progressive MS (PMS; n = 922), and primary progressive MS (PPMS; n = 1,171), with a data cutoff of November 2022, were included in the individual patient analyses. For all trials, T25FWT events were associated with increased risk of subsequent EDSS events (hazard ratios [HRs], p values: 2.11-5.20, 0.07-<0.001); similar associations were found for 9HPT events with HRs for later EDSS events ranging from 1.47 to 2.66 (p values from 0.24-<0.001). For patients without EDSS events in the first 96 study weeks, T25FWT or 9HPT events in the first 96 study weeks were associated with increased risk of subsequent EDSS events (HRs, p values: T25FWT 1.74-3.26, 0.01-<0.001; 9HPT 1.45-3.08, 0.45-<0.001). Patients with T25FWT or 9HPT events were more likely to experience a ≥8-point change from baseline at the final visit in the 29-item Multiple Sclerosis Impact Scale physical subscale (risk ratios, p values: T25FWT 1.45-2.17, 0.004-<0.001; 9HPT 1.26-1.87, 0.15-0.03). Analysis (ii): In the 9 studies included, treatment effects on T25FWT events were predictive of treatment effects on EDSS events (Spearman correlation [95% CI] = 0.82 [0.34-0.96], p = 0.005). DISCUSSION: In this post hoc analysis, worsening on T25FWT or 9HPT was a harbinger of EDSS worsening and treatment effects on T25FWT correlated with those on EDSS. These results establish the predictive validity and clinical relevance of performance-test worsening, thus supporting use of cCDW/cCDP as a primary outcome for progression in MS trials. CLINICAL TRIAL IDENTIFIERS: ClinicalTrials.gov Identifiers: NCT01247324 (OPERA I); first submitted November 23, 2010; first patient enrolled: August 31, 2011; available at clinicaltrials.gov/study/NCT01247324. NCT01412333 (OPERA II); first submitted August 8, 2011; first patient enrolled: September 20, 2011; available at clinicaltrials.gov/study/NCT01412333. NCT03085810 (ENSEMBLE); first submitted March 16, 2017; first patient enrolled: March 27, 2017; available at clinicaltrials.gov/study/NCT03085810. NCT01194570 (ORATORIO); first submitted August 28, 2010; first patient enrolled: March 3, 2011; available at clinicaltrials.gov/study/NCT01194570. NCT03523858 (CONSONANCE); first submitted April 16, 2018; first patient enrolled: May 28, 2018; available at clinicaltrials.gov/study/NCT03523858. NCT00087529 (OLYMPUS); first submitted July 9, 2004; first patient enrolled: July 9, 2004; available at clinicaltrials.gov/study/NCT00087529.
引用
- Kappos L, Yiu S, Dahlke F, et al. Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials. Neurology. 2025. PMID: 40258203. doi:10.1212/WNL.0000000000213558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。